We are live on ! Find out more
JHIU

Janus Henderson Investors US Portfolio holdings

AUM $122B
1-Year Est. Return 18.26%
This Fund
S&P 500
This Quarter Est. Return
+4.99%
1 Year Est. Return
+18.26%
3 Year Est. Return
+41.86%
5 Year Est. Return
10 Year Est. Return
AUM
$109B
AUM Growth
+$1.63B
Cap. Flow
-$2.98B
Cap. Flow %
-2.73%
Top 10 Hldgs %
13.68%
Holding
1,141
New
86
Increased
455
Reduced
516
Closed
52

Sector Composition

Rank Sector Weight
1 Healthcare 16.92%
2 Technology 14.89%
3 Industrials 12.48%
4 Financials 11.62%
5 Consumer Discretionary 10.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WCN
651
Waste Connections
WCN
$42B
$11.1M 0.01%
343,800
-41,700
-11% -$1.25M
BWXT icon
652
BWX Technologies
BWXT
$15.5B
$11.1M 0.01%
478,675
-31,875
-6% -$756K
VER
653
DELISTED
VEREIT, Inc.
VER
$11.1M 0.01%
177,312
+162,099
+1,066% +$10.4M
XYL icon
654
Xylem
XYL
$28.3B
$11.1M 0.01%
284,200
+195,500
+220% +$7.3M
SLXP
655
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$11M 0.01%
89,500
-161,516
-64% -$17.9M
GMCR
656
DELISTED
KEURIG GREEN MTN INC
GMCR
$11M 0.01%
88,000
-129,644
-60% -$14.1M
SBNY
657
DELISTED
Signature Bank
SBNY
$10.9M 0.01%
86,700
+22,800
+36% +$2.74M
QVCGA
658
DELISTED
QVC Group Inc Series A
QVCGA
$10.8M 0.01%
8,954
-3,317
-27% -$3.96M
IPGP icon
659
IPG Photonics
IPGP
$3.69B
$10.7M 0.01%
156,214
-35,109
-18% -$2.37M
UTHR icon
660
United Therapeutics
UTHR
$22.3B
$10.7M 0.01%
121,100
-151,000
-55% -$14.5M
EXAS
661
DELISTED
Exact Sciences
EXAS
$10.7M 0.01%
628,850
-195,116
-24% -$2.69M
NBIX icon
662
Neurocrine Biosciences
NBIX
$16.1B
$10.7M 0.01%
721,488
+47,824
+7% +$675K
ETN icon
663
Eaton
ETN
$180B
$10.7M 0.01%
138,357
-322,712
-70% -$24M
HES
664
DELISTED
Hess
HES
$10.6M 0.01%
106,800
-29,200
-21% -$2.63M
LM
665
DELISTED
Legg Mason, Inc.
LM
$10.6M 0.01%
205,800
+181,600
+750% +$8.76M
RSG icon
666
Republic Services
RSG
$66.2B
$10.6M 0.01%
277,990
-931,133
-77% -$33M
ED icon
667
Consolidated Edison
ED
$39.8B
$10.5M 0.01%
182,700
+14,300
+8% +$798K
J icon
668
Jacobs Solutions
J
$16.9B
$10.5M 0.01%
239,285
-395,828
-62% -$18.8M
ZQK
669
DELISTED
QUICKSILVER,INC.
ZQK
$10.4M 0.01%
2,913,140
-1,725,657
-37% -$9.69M
MKL icon
670
Markel Group
MKL
$22.9B
$10.4M 0.01%
15,900
+1,500
+10% +$945K
WLK icon
671
Westlake Corp
WLK
$9.99B
$10.4M 0.01%
124,400
+69,700
+127% +$5.22M
KERX
672
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$10.4M 0.01%
676,690
+22,456
+3% +$318K
RMAX icon
673
RE/MAX Holdings
RMAX
$260M
$10.4M 0.01%
350,878
-10,166
-3% -$288K
SMG icon
674
ScottsMiracle-Gro
SMG
$3.59B
$10.3M 0.01%
181,700
+69,900
+63% +$4.18M
EAT icon
675
Brinker International
EAT
$10B
$10.3M 0.01%
212,200
+134,500
+173% +$6.74M

Similar funds

Janus Henderson Investors US's Q2 2014 Portfolio in Review

As of Q2 2014, Janus Henderson Investors US held 1,141 positions worth $109B, up 1.5% from $107B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Janus Henderson Investors US's Q2 2014 filing shows 86 new, 455 increased, 516 reduced and 52 closed positions. Its largest new stake was Lands' End: 3,215,073 shares worth $108M. The largest sale was Gilead Sciences, an estimated $420M.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 17% a quarter earlier, followed by Technology and Industrials.

  • Janus Henderson Investors US's largest Q2 2014 buy was Lands' End: 3,215,073 shares worth $108M.
  • Janus Henderson Investors US added most to Meta Platforms (Facebook) in Q2 2014, an estimated $245M increase.
  • Janus Henderson Investors US's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $420M.
  • Janus Henderson Investors US fully exited CIT Group Inc. in Q2 2014, selling an estimated $124M.
  • Janus Henderson Investors US's ten largest holdings make up 14% of its $109B portfolio in Q2 2014.
  • Janus Henderson Investors US opened 86 new positions and closed 52 in Q2 2014.
  • Janus Henderson Investors US's portfolio value rose 1.5% quarter-over-quarter to $109B.

Based on Janus Henderson Investors US's 13F filing for Q2 2014, filed 14 Aug 2014.